null

Farletuzumab Biosimilar (Anti-FOLR1) Antibody (HDBS0144)

SKU:
HDBS0144
Antibody Type:
Biosimilar Reference Antibody
Applications:
IHC
FC
Drug Development
Pharmacokinetics
Disease Area:
Cancer
Disease Area:
Folate Deficiency Disorders
Protein:
FOLR1
Reactivity:
Human
Host Species:
Humanized
Isotype:
IgG1
€399

Description

system_update_altDatasheet

Farletuzumab (Anti-FOLR1) Biosimilar Antibody (HDBS0144)

The Farletuzumab Biosimilar Anti-FOLR1 Antibody is a cutting-edge research tool designed for the study of FOLR1, a cell surface receptor overexpressed in various cancers, including ovarian and breast cancer. This monoclonal antibody, developed for accuracy and specificity, is ideal for research applications such as immunohistochemistry, flow cytometry, and ELISA.FOLR1, also known as folate receptor alpha, is a promising target for cancer therapy due to its high expression in tumor cells and limited expression in normal tissues. Research on FOLR1 has shown potential in the development of targeted therapies for cancer treatment, making this antibody a valuable tool for investigating the role of FOLR1 in cancer biology and assessing its potential as a therapeutic target.

The Farletuzumab Biosimilar Anti-FOLR1 Antibody offers researchers a reliable tool for the detection and analysis of FOLR1 in various cell types and tissues, providing valuable insights into its function and potential as a target for cancer therapy. Its high specificity and sensitivity make it a valuable resource for studies in cancer research and the development of novel treatments for FOLR1-positive cancers.